CD19 and B-cell chronic lymphocytic leukemia: Although CD19-directed CAR T-cell therapy has been transformative in other B-cell malignancies, its efficacy in CLL has been tempered by T-cell dysfunction, antigen loss, and immune suppressive effects of the CLL microenvironments [32].